Mineralys Therapeutics (MLYS) Projected to Post Quarterly Earnings on Monday

Mineralys Therapeutics (NASDAQ:MLYS) is expected to release its Q3 2025 results before the market opens on Monday, November 10th. Analysts expect Mineralys Therapeutics to post earnings of ($0.71) per share for the quarter. Interested persons can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Monday, November 10, 2025 at 4:30 PM ET.

Mineralys Therapeutics (NASDAQ:MLYS) last posted its earnings results on Tuesday, August 12th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.12. On average, analysts expect Mineralys Therapeutics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Mineralys Therapeutics Stock Performance

Mineralys Therapeutics stock opened at $40.86 on Monday. Mineralys Therapeutics has a one year low of $8.24 and a one year high of $44.80. The company has a 50-day simple moving average of $36.16 and a 200-day simple moving average of $22.12. The firm has a market capitalization of $2.71 billion, a P/E ratio of -11.48 and a beta of 0.40.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on MLYS shares. Jefferies Financial Group boosted their price objective on Mineralys Therapeutics from $15.00 to $26.00 and gave the stock a “hold” rating in a research report on Wednesday, September 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Mineralys Therapeutics in a research report on Wednesday, October 8th. Bank of America lifted their price objective on shares of Mineralys Therapeutics from $38.00 to $43.00 and gave the company a “buy” rating in a research note on Thursday, August 28th. HC Wainwright increased their price objective on shares of Mineralys Therapeutics from $42.00 to $52.00 and gave the company a “buy” rating in a report on Thursday. Finally, Wells Fargo & Company upped their price target on shares of Mineralys Therapeutics from $26.00 to $50.00 and gave the company an “overweight” rating in a report on Thursday, September 11th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $45.17.

Insider Activity at Mineralys Therapeutics

In other Mineralys Therapeutics news, Director Srinivas Akkaraju acquired 588,235 shares of the business’s stock in a transaction that occurred on Thursday, September 4th. The shares were purchased at an average price of $25.50 per share, with a total value of $14,999,992.50. Following the completion of the transaction, the director owned 588,235 shares in the company, valued at $14,999,992.50. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Ra Capital Management, L.P. bought 1,176,470 shares of Mineralys Therapeutics stock in a transaction on Thursday, September 4th. The stock was acquired at an average price of $25.50 per share, with a total value of $29,999,985.00. Following the completion of the purchase, the director directly owned 5,456,521 shares of the company’s stock, valued at approximately $139,141,285.50. The trade was a 27.49% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last three months, insiders sold 58,959 shares of company stock worth $2,098,393. 25.56% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Mineralys Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of MLYS. The Manufacturers Life Insurance Company increased its position in Mineralys Therapeutics by 29.8% during the second quarter. The Manufacturers Life Insurance Company now owns 14,775 shares of the company’s stock worth $200,000 after buying an additional 3,390 shares during the last quarter. Federated Hermes Inc. raised its stake in shares of Mineralys Therapeutics by 38.3% in the 2nd quarter. Federated Hermes Inc. now owns 16,528 shares of the company’s stock valued at $224,000 after acquiring an additional 4,577 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Mineralys Therapeutics by 4.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,085 shares of the company’s stock worth $271,000 after purchasing an additional 702 shares during the period. Man Group plc grew its holdings in Mineralys Therapeutics by 50.1% during the second quarter. Man Group plc now owns 21,852 shares of the company’s stock valued at $296,000 after purchasing an additional 7,293 shares during the last quarter. Finally, Creative Planning acquired a new stake in shares of Mineralys Therapeutics in the second quarter worth $336,000. Institutional investors and hedge funds own 84.46% of the company’s stock.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.